Aurinia Pharmaceuticals Inc. Insider Sells Stock Worth Over $68,000

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has recently seen an insider trade involving Greg Keenan. On March 7th, Mr. Keenan sold a total of 8,305 shares of the company's stock for an average price of $8.23 per share, amounting to a total value of $68,350.15. Following this transaction, Keenan now holds 153,484 shares in Aurinia Pharmaceuticals, valued at approximately $1,263,173.32. This sale also indicates a 5.13% reduction in his ownership stake in the company.

The details of this transaction were made publicly available through a filing with the Securities and Exchange Commission (SEC).

Aurinia Pharmaceuticals Stock Performance

On the day of the transaction, Aurinia Pharmaceuticals stock experienced a slight decline of $0.04, closing at $8.15. The trading volume for the day reached 1,152,887 shares, which is lower than the average trading volume of 1,481,486 shares. As of now, the fifty-day moving average price stands at $8.10, while the two-hundred day moving average price is $7.86.

Institutional Trading Overview

Recent activities by institutional investors show increased interest in Aurinia Pharmaceuticals. For instance, State Street Corp has raised its stake by 2.3% in the third quarter and now owns approximately 2,945,060 shares valued at around $21,587,000. Barclays PLC significantly boosted its stake by 187.6%, acquiring an additional 143,072 shares to hold a total of 219,331 shares valued at $1,607,000.

Summary of Analyst Ratings

In terms of analyst coverage, StockNews.com recently adjusted the rating of Aurinia Pharmaceuticals. The company's stock was downgraded from a strong-buy to a buy rating on February 19th. This shift underscores the mixed sentiments among analysts regarding the company's future performance.

Company Overview

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing therapies for diseases that require better medical solutions. The company primarily offers LUPKYNIS, a treatment for adults suffering from active lupus nephritis. Additionally, Aurinia has a collaboration agreement with Otsuka Pharmaceutical Co., Ltd.

Aurinia, Insider, Stock